CDSCO Panel nod granted for Lumateperone Capsule

The positive results from these trials were instrumental in convincing the CDSCO's Subject Expert Committee (SEC) to grant marketing authorization.

0
CDSCO Panel
CDSCO Panel

Last Updated on November 17, 2024 by The Health Master

CDSCO

Sun Pharmaceutical Industries Ltd., a leading global pharmaceutical company, has received a significant regulatory approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market Lumateperone capsules 42 mg.

This innovative drug is designed to treat a range of neuropsychiatric disorders, including schizophrenia.

Understanding Lumateperone

Lumateperone is a novel antipsychotic medication that works by modulating multiple neurotransmitter systems.

It targets dopamine, serotonin, and glutamate receptors, offering a unique mechanism of action compared to traditional antipsychotics.

This multi-target approach is believed to provide more comprehensive symptom relief and fewer side effects.

The Road to Approval

Sun Pharma’s journey to securing approval for Lumateperone involved rigorous clinical trials.

The company conducted extensive Phase III clinical trials to evaluate the drug’s safety, efficacy, and tolerability.

The positive results from these trials were instrumental in convincing the CDSCO’s Subject Expert Committee (SEC) to grant marketing authorization.

Key Conditions for Approval

While the CDSCO has given the green light to Sun Pharma, the approval is subject to certain conditions:

  • Phase IV Clinical Trial: Sun Pharma is required to conduct a Phase IV clinical trial to further assess the long-term safety and efficacy of Lumateperone. This post-marketing study will provide valuable real-world data on the drug’s performance.
  • Restricted Prescription: Lumateperone will be available only through prescription from a qualified neurologist or psychiatrist. This ensures that the drug is used appropriately and under medical supervision.

A Promising Future for Neuropsychiatric Disorder Treatment

The approval of Lumateperone represents a significant milestone in the treatment of neuropsychiatric disorders.

This innovative drug has the potential to improve the lives of countless patients suffering from conditions like schizophrenia.

As Sun Pharma continues to gather more data on Lumateperone’s long-term effects, the future looks promising for patients seeking effective and well-tolerated treatment options.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

Disclaimer: This content, provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information. The Health Master does not claim responsibility for this information.

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news